李氏大藥廠(00950.HK):兆科眼科已向聯交所遞交主板上市申請
格隆匯 12 月 18日丨李氏大藥廠(00950.HK)公佈,有關可能將兆科眼科分拆及獨立上市。於2020年12月18日向聯交所呈交上市申請表格(A1表格),以申請批准兆科普通股以全球發售方式於聯交所主板上市及買賣。
經適當及審慎考慮建議分拆,並適當考慮股東的利益後,倘進行建議分拆,則計劃在兆科眼科的董事會決定進行建議分拆及全球發售,以及上市委員會批准上市等若干條件的規限下,以根據全球發售優先發售兆科普通股的方式,向合資格現有股東提供兆科普通股保證配額。有關保證配額的詳情尚未落實。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.